Atypical type III hyperlipoproteinemia in a patient with Ig A myelomatosis.
We studied a 58-year-old woman with severe therapy-refractory hyperlipidemia, xanthomatosis, and multiple myeloma (immunoglobulin A, lambda light chain). The lipid disorder became evident about half a year prior to the expression of myelomatosis. Clinical symptoms were similar to those found in classical type III hyperlipoproteinemia but the underlying metabolic defect was different from the one described in this primary dyslipoproteinemia. The patient has the heterozygous apolipoprotein E3/2 phenotype and her VLDL-cholesterol/serum-triglyceride ratio is unusually low at 0.05. Evidence is given that the hyperlipoproteinemia is due to an impaired catabolism of intermediate density lipoproteins probably because of a reduced hepatic triglyceride lipase activity.
Feussner
G
G
Medizinische Klinik, Universität Heidelberg.
von Hodenberg
E
E
Ziegler
R
R
D015243:Cholesterol, VLDL / Q000097:blood; D005260:Female; D006801:Humans; D006952:Hyperlipoproteinemia Type III / Q000201:enzymology*; D007070:Immunoglobulin A / Q000032:analysis*; D008049:Lipase / Q000172:deficiency*; D008074:Lipoproteins / Q000097:blood; D008099:Liver / Q000201:enzymology; D008875:Middle Aged; D009101:Multiple Myeloma / Q000201:enzymology*; D014280:Triglycerides / Q000097:blood
D015243:Cholesterol, VLDL; D007070:Immunoglobulin A; D008074:Lipoproteins; D014280:Triglycerides; D008049:Lipase